• News
  • Technology
  • Culture
  • Entertainment
  • Sport
  • Travel
  • Music
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Monday, January 30, 2023
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
ADVERTISEMENT
Home Business Pharmacy

Boehringer Ingelheim positioned for future growth with product launches

by The FINANCIAL
April 23, 2015
in Pharmacy
0
Share on FacebookShare on Twitter

The FINANCIAL — With numerous marketing authorisations for medicines and product launches in 2014, the research-driven pharmaceutical company Boehringer Ingelheim is now positioned for future growth. “After a challenging 2014, the focus for us now is on launching numerous additional new products and on our profitability,” said Professor Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim, at the Annual Press Conference today. “We were able to submit a large number of compounds for marketing authorisation in 2014 and, with research and development expenditure amounting to just close to 2.7 billion euros, we have invested once again in the future.”

In 2014, the company generated net sales of around 13.3 billion euros, which, currency-adjusted, represented a decline of 3.2 per cent
(- 5.3 per cent in euro terms). This resulted in an operating income of some 2.1 billion euros and a return on net sales of 16.1 per cent. For the current financial year, the company expects a moderate increase in net sales compared with the previous year. Boehringer Ingelheim employed more than 47,700 people worldwide in 2014, which is roughly one per cent more than in 2013, according to Boehringer Ingelheim.

Many additional product launches planned

RelatedPosts

Roche ranked the most sustainable healthcare company in the DJSI

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

Boehringer Ingelheim last year submitted a large number of new medicines for marketing authorisation. Medicines launched in the last few months include STRIVERDI RESPIMAT for patients suffering from chronic obstructive pulmonary disease (COPD), JARDIANCE and GLYXAMBI, a combination of the active ingredients linagliptin and empagliflozin, for the treatment of type 2 diabetes, OFEV for the treatment of idiopathic pulmonary fibrosis (IPF) and, at the beginning of January 2015, VARGATEF for the treatment of advanced lung cancer patients with adenocarcinoma after chemotherapy.

Many challenges brought to a successful conclusion

In business terms, research-driven pharmaceutical companies found themselves confronted with a rapidly changing market environment in 2014 – foremost in the USA. This was due in part to tougher regulation, which led to additional pressure on the pharmaceutical business as a whole. “We responded to the rapidly changing market environment quickly and effectively with a heightened awareness of costs,” said Hubertus von Baumbach, Member of the Board of Managing Directors responsible for the Corporate Board Division Finance.

Boehringer Ingelheim’s equity was up 14 per cent in 2014 to 8.1 billion euros. The equity ratio also rose to 40 per cent. The increase in financial funds to 8.5 billion euros will secure the company’s independence and provide the financial flexibility needed for future growth. Overall, this underscores the group’s sound financing.

Cash flow from operating activities, at 2 billion euros, remained at a high level. Looking ahead to future developments, Boehringer Ingelheim invested in the expansion of its production capacity, for example for the manufacture of the RESPIMAT inhaler at its locations in Dortmund and Ingelheim.

Prescription Medicines most important business mainstay

Boehringer Ingelheim last year generated net sales of 10.1 billion euros in Prescription Medicines, its most important business. At
3.2 billion euros, SPIRIVA for the treatment of COPD remains the company’s best-selling product. One of the main growth drivers in this business in the years to come will be products for the treatment of diabetes. In 2014, the TRAJENTA/JENTADUETO product family for the treatment of type 2 diabetes already generated an increase in net sales, currency-adjusted, of around 37 per cent to 636 million euros
(+ 34.2 per cent in euro terms). The anticoagulant PRADAXA contributed 1.2 billion euros to net sales. “We now have many products from recent development on the market. For the coming five years, we plan, however, to markedly renew our sales drivers,” said von Baumbach. “Our successes in research and development are the drivers of this.”

With net sales of over 1.4 billion euros, business in Consumer Health Care medicines accounted for 11 per cent of the group’s net sales. Driven primarily by the core global brands BUSCOPAN, DULCOLAX, MUCOSOLVAN and PHARMATON, net sales, currency-adjusted, were up 2 per cent (- 2.5 per cent in euro terms).

In its Animal Health business, Boehringer Ingelheim in 2014 once again generated net sales of over one billion euros. This corresponds to a currency-adjusted increase of 6.8 per cent (+ 5.6 per cent in euro terms) and 8 per cent of the group’s total net sales. The business outperformed the market.1 Net sales in the small animal business rose by a currency-adjusted 18.1 per cent (+ 17.2 per cent in euro terms) and was thereby the main growth driver. The greatest growth here was achieved with the dog vaccine DURAMUNE® for protection against infectious diseases. Net sales increased by a currency-adjusted 33.1 per cent (+ 32.3 per cent in euro terms) to 69 million euros.

Boehringer Ingelheim generated net sales of 501 million euros in 2014 with the contract manufacturing of biopharmaceuticals.

USA, Japan and Germany are the top three sales markets

The three most important markets – USA, Japan and Germany – accounted for around 55 per cent of Boehringer Ingelheim’s total net sales in 2014, with net sales of around 912 million euros generated in Germany, net sales of around 1.7 billion euros in Japan and around 4.6 billion euros in the USA.

Outlook 2015

In view of the numerous changes in the healthcare systems, there are currently no signs of any significant growth in the pharmaceutical industry. “In our view, Boehringer Ingelheim is well-positioned for future growth,” said Professor Barner. “Despite the difficult market environment, we are therefore planning in 2015 for a moderate increase in net sales compared with the previous year.”

 

ADVERTISEMENT
The FINANCIAL

The FINANCIAL

Related Posts

Roche ranked the most sustainable healthcare company in the DJSI
Pharmacy

Roche ranked the most sustainable healthcare company in the DJSI

by The FINANCIAL
November 16, 2020
0

The FINANCIAL -- For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index...

Read more
Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

November 16, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

November 12, 2020
Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

November 12, 2020
Next Post

Acer Unveils Aspire Notebook Lineup with Solid Performance and Stylish Design

Please login to join discussion
ADVERTISEMENT
  • Trending
  • Comments
  • Latest
Vaccination

How many people died after COVID-19 Vaccination?

November 20, 2021
How to Check KRA Pin Using ID Number

How to Check KRA Pin Using ID Number

June 25, 2018
Full-dose blood thinners not a cure for critically ill COVID-19 patients

How many people have died as a result of a COVID-19 vaccine?

October 4, 2021
Rishi Sunak’s billionaire wife also runs these three companies. 

Rishi Sunak’s billionaire wife also runs these three companies. 

October 25, 2022
Startled sherman furnished repair gang kansas

Startled sherman furnished repair gang kansas

0
Ft. trace falling nixon recovery sacred

Ft. trace falling nixon recovery sacred

0
FIFA 16 review: A mammoth footy bit of magic

Prepare mounted cited perspective

0
Protest threatened hurt conferences observation precise

Protest threatened hurt conferences observation precise

0
What are the top 3 strategies for business automation?

Protected: Want Loyal Employees? Do This

January 26, 2023
Fugitive Extradited from Cameroon to the United States to Serve 80 Year Prison Sentence

Second Bank Employee Admits Role in Fraud Conspiracy

January 25, 2023
Sussex County Woman Sentenced to 34 Months in Prison for Concealing Terrorist Financing to Syrian Foreign Terrorist Organizations

Sussex County Woman Sentenced to 34 Months in Prison for Concealing Terrorist Financing to Syrian Foreign Terrorist Organizations

January 25, 2023
Brooklyn Park Man Pleads Guilty to His Role in $250 Million Feeding Our Future Fraud Scheme

Brooklyn Park Man Pleads Guilty to His Role in $250 Million Feeding Our Future Fraud Scheme

January 25, 2023

Popular Last 24h

  • EasyJet to fly to London from Stockholm Arlanda

    The London Diplomatic List, Addresses, Contacts & Working Hours

    0 shares
    Share 0 Tweet 0
  • Pfizer Names Albert Bourla Chief Operating Officer

    0 shares
    Share 0 Tweet 0
  • How to Check KRA Pin Using ID Number

    0 shares
    Share 0 Tweet 0
  • 5 Assets To Store Your Wealth During Times Of Crisis

    0 shares
    Share 0 Tweet 0
  • Research: Is Portuguese real estate worth buying right now? (2022, Q3)

    0 shares
    Share 0 Tweet 0
  • Nearly 900 Million Worldwide Wanted to Migrate in 2021

    0 shares
    Share 0 Tweet 0
  • YouPorn made TikTok like app for adults

    0 shares
    Share 0 Tweet 0

LATEST POSTS

What are the top 3 strategies for business automation?

Protected: Want Loyal Employees? Do This

January 26, 2023
Fugitive Extradited from Cameroon to the United States to Serve 80 Year Prison Sentence

Second Bank Employee Admits Role in Fraud Conspiracy

January 25, 2023
Sussex County Woman Sentenced to 34 Months in Prison for Concealing Terrorist Financing to Syrian Foreign Terrorist Organizations

Sussex County Woman Sentenced to 34 Months in Prison for Concealing Terrorist Financing to Syrian Foreign Terrorist Organizations

January 25, 2023
Brooklyn Park Man Pleads Guilty to His Role in $250 Million Feeding Our Future Fraud Scheme

Brooklyn Park Man Pleads Guilty to His Role in $250 Million Feeding Our Future Fraud Scheme

January 25, 2023
Former CEO Of Email Security Company Sentenced To Five Years In Prison

Former CEO Of Email Security Company Sentenced To Five Years In Prison

January 25, 2023
Proven Forex Trading Strategies for Beginners

Trusted B2B Trading Platform

January 25, 2023
Part-time working can boost economy and bring economically inactive people back into work

Part-time working can boost economy and bring economically inactive people back into work

January 25, 2023
How to unlock your full investment potential

How to unlock your full investment potential

January 25, 2023
IFC, Canada Continue Supporting Sustainable Energy Financing in Lebanon

Nearly 900 Million Worldwide Wanted to Migrate in 2021

January 24, 2023
65% of Europeans see EU membership as a good thing, the highest result since 2007 

IPSOS Poll: Despite some softening, support for Ukraine is still strong across western countries

January 23, 2023

LATEST INTERVIEWS

Russian Patriarch Kirill Says Dying In Ukraine ‘Washes Away All Sins’

Interview: Why Putin Might Prefer A Stalemate To Going Nuclear On Ukraine

by The FINANCIAL
October 22, 2022
0

Kvaratskhelia Football Dynasty: Mamia, Badri, Khvicha and Tornike

Kvaratskhelia Football Dynasty: Mamia, Badri, Khvicha and Tornike

by Tengiz Pachkoria
August 11, 2022
0

“Green business is a key instrument to support business development in a sustainable way”

“Green business is a key instrument to support business development in a sustainable way”

by The FINANCIAL
July 27, 2022
0

Running an environmentally friendly business helps to reduce impact on the environment

Running an environmentally friendly business helps to reduce impact on the environment

by The FINANCIAL
July 27, 2022
0

Georgian Industrial Group Continuing to Implement Energy Efficient Projects and Contribute to Sustainable Business Development

Georgian Industrial Group Continuing to Implement Energy Efficient Projects and Contribute to Sustainable Business Development

by The FINANCIAL
July 27, 2022
0

“We have planted under 50 000 trees and seedings”

“We have planted under 50 000 trees and seedings”

by The FINANCIAL
July 27, 2022
0

The Committee on the Environment and Natural Resources of Georgia – The Role of the Public Sector in Promoting Green Business

The Committee on the Environment and Natural Resources of Georgia – The Role of the Public Sector in Promoting Green Business

by The FINANCIAL
July 27, 2022
0

Leading the way for Green Corporate Culture, With 100-step Environmental Program Completed RMG enters the New Phase of Green Development

Leading the way for Green Corporate Culture, With 100-step Environmental Program Completed RMG enters the New Phase of Green Development

by The FINANCIAL
July 27, 2022
0

Newsletter

ADVERTISEMENT

GET IN TOUCH

E-mail your company news at:

news (at) financial.ge Letters to the Editor: editor (at) finchannel.com

Local Marketing contact:

(+99532) 2252 275 | 76 EXT: 1 (+995 558) 03 03 03 (mobile) marketing (at) finchannel.com

Requests from abroad:

(+99532) 2252 275 | 76 EXT: 7 (+995599) 96 52 52 Email: zviadi (@) finchannel.com Contact video editor: E-mail: video (at) financial.ge

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.